ClinicalTrials.gg
Not yet recruitingNCT07851376Updated Oct 1, 2026

Multi-Modal Digital Monitoring of Disease Symptoms in Spinocerebellar Ataxia

An observational study in Spinocerebellar Ataxia (SCA), sponsored by BioSensics. Not yet recruiting at 2 sites in United States. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-10-01.

Sponsored by BioSensics · Observational

How we know

Updated Oct 1, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
25
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 36 studies in Spinocerebellar Ataxias with a site in United States — 7 open to participants now, 14 under way, 2 of them phase 3. Spinocerebellar Ataxias · United States.

Planned enrollment
10th of 14
25 · median 164
Started
2026
with 5 others
Observational
14 of 36
3 open now
Primary completion
2028-12
later than 7 of 13 live
Registered
35th of 36
by date
Lead sponsor
1 of 36
BioSensics

Among the 36 studies in Spinocerebellar Ataxias with a site in United States, this one is the 10th largest by planned enrollment of the 14 observational ones that give a count, is one of 6 that started in 2026, is one of 14 observational ones, reaches primary completion later than 7 of the 13 other live ones, and was the 35th registered.

Spinocerebellar Ataxias

95 studies on the registry are indexed under Spinocerebellar Ataxias; 25 are open to participants now.

Browse Spinocerebellar Ataxias studies →

Open to participants now

7 of the 36 studies in Spinocerebellar Ataxias with a site in United States are open now. Recruiting first, the newest first:

1 more — sign in →

All 7 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 16 Spinocerebellar Ataxias studies recruiting now, 8 (50%) set no upper age limit and 3 (19%) stop at 75 or younger; 4 take children under 18; 5 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 36 studies in Spinocerebellar Ataxias with a site in United States, or all of them as a file.
02

Study summary

This is an observational study. Subjects with a documented diagnosis of spinocerebellar ataxia (SCA) will be screened and recruited to participate at two clinical sites: Johns Hopkins University (JHU) and Columbia University (CU).

Researchers at BioSensics, JHU, and CU will use wearable sensors computerized speech, psychomotor, and ocular assessments to evaluate the feasibility of using digital health technologies to monitor symptoms in SCA. Researchers will also measure the Scale for the Assessment and Rating of Ataxia (SARA) and other SCA clinical assessments.

The solution will be deployed for 25 participants with SCA for approximately 12 months with 5 study visits (Screening/Baseline, Day 1, Day 30, Day 90, Day 180, Day 360).

Read the detailed description

The spinocerebellar ataxias (SCAs) are a clinically and genetically heterogeneous group of rare, autosomal dominant neurodegenerative disorders characterized by progressive degeneration of the cerebellum and its connecting pathways. The four most common subtypes (SCA1, SCA2, SCA3, and SCA6) are caused by expanded polyglutamine-coding CAG repeats, and collectively account for the majority of dominantly inherited ataxias worldwide. The cardinal feature across subtypes is progressive ataxia affecting gait, stance, limb coordination, and speech, frequently accompanied by oculomotor abnormalities and, in some subtypes, extracerebellar signs such as spasticity, peripheral neuropathy, and parkinsonism. Symptoms typically begin in adulthood and progress over many years, leading to severe disability and reduced life expectancy.

The principal means of measuring ataxia severity is the Scale for the Assessment and Rating of Ataxia (SARA), which is the most widely applied clinical outcome assessment (COA) for genetic ataxias and has been used as the primary endpoint in large natural history cohorts and randomized controlled trials. Although the SARA has demonstrated good inter-rater reliability and has been validated across multiple SCA subtypes, it is inherently subjective and semi-quantitative, requires trained personnel to administer, and may not be sufficiently sensitive to detect incremental but clinically meaningful changes over short follow-up intervals.

Movement-associated symptoms are a core feature of SCA and have a substantial negative impact on quality of life. Impairments in gait and balance contribute to falls and loss of independence, while dysarthria and impaired limb coordination affect communication and activities of daily living. Because these assessments are conducted infrequently, typically in a clinic setting, they may not accurately represent an individual's true functional status during everyday life. However, the increasing understanding of disease pathomechanisms and the development of gene-targeting and other novel therapeutic approaches have raised expectations for disease-modifying treatments. The key challenge in developing new therapeutics for SCA and other neurological disorders is that current disease assessment is largely subjective and requires in-person, in-clinic evaluation.

Digital measures, such as those proposed in this study, can provide objective, sensitive, and real-world assessments of how individuals are functioning. A growing body of evidence demonstrates that digital biomarkers derived from body-worn inertial sensors can quantify ataxia-specific gait and balance impairments, and correlate strongly with clinician-rated SARA scores.

Beyond gait and balance, multi-modal digital assessment of speech, hand function, and oculomotor control may capture complementary domains of cerebellar dysfunction that are affected in SCA. Acoustic analysis of speech can quantify dysarthria, finger tapping can characterize upper-limb bradykinesia and dysrhythmia, and oculomotor testing can capture saccadic and antisaccadic abnormalities that are characteristic of cerebellar disease.

Thus, a system that can objectively, sensitively, and frequently monitor multiple clinical domains (motor, speech, and oculomotor function) is necessary to understand the pattern of evolving impairment in individuals with SCA and to support the identification of endpoint measures for therapeutic trials. This study will evaluate the feasibility of a multi-modal digital monitoring platform in a cohort of individuals with SCA and will characterize the relationship between digital measures and established clinical and patient reported outcomes.

03

Conditions studied

  • Spinocerebellar Ataxia (SCA)

Keywords

  • digital health
  • wearable sensors
  • spinocerebellar ataxia
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Adults with SCA

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female, aged 18-75 years
  • Fluent in English (able to speak and read)
  • Able to ambulate at least 10 meters independently or with a cane, without other assistive devices, as determined by the investigator
  • Able to independently perform all study activities safely, as determined by the investigator
  • Willing and able to provide and comply with all study procedures
  • Genetically or clinically confirmed diagnosis of spinocerebellar ataxia (SCA 1, 2, 3, or 6)

Exclusion criteria

Exclusion Criteria:

  • Individuals who are unable to ambulate at least 10 meters independently or with a cane.
  • Individuals with a neurological, medical, or psychiatric condition (other than SCA) that, in the investigator's judgment, would interfere with safe participation in study activities or confound the assessment of ataxia
  • Pregnant individuals, due to potential changes in gait and physical activity during pregnancy
  • Any condition that, in the investigator's judgment, would prevent the participant from completing the study procedures safely
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
25 participants (estimated)
Patient registry
No
Biospecimen retention
Samples with dna
06

What researchers measure

Primary outcomes

  1. Physical Activity Monitoring - Daily Number of Steps (count)

    Following each clinical visit, participants will be asked to wear a PAMSys pendant sensor, PAMSys ULM wrist sensors, and PAMSys Gait for 7 days at home. The average daily number of steps will be measured using the PAMSys pendant.

    Time frame: 12 months

  2. Physical Activity Monitoring - Total number of goal-directed movement (GDM)

    Following each clinical visit, participants will be asked to wear a PAMSys ULM sensor, a wearable sensor for long-term monitoring of upper limb and activities of daily living (ADL). The sensor will record the daily number GDMs as participants perform ADLs.

    Time frame: 12 months

  3. Physical Activity Monitoring - Stride Velocity (m/s)

    Following each clinical visit, participants will be asked to wear a PAMSys Gait sensor, a wearable sensor for long-term monitoring of gait during activities of daily living (ADL). The sensor will record the average stride velocity (m/s) during ADLs.

    Time frame: 12 months

Secondary outcomes

  1. Scale for the Assessment and Rating of Ataxia (SARA)

    The SARA is an 8-item clinical sale to measure severity and progression of cerebellar ataxia. Total scores range from 0 (no ataxia) to 40 (most severe ataxia).

    Time frame: 12 months

  2. Digital Speech Assessment - Intelligibility (%)

    Using a study tablet, participants will read the Rainbow Passage. Intelligibility is a digital measure of speech clarity that determines how easily a listener can understand spoken words. Intelligibility ranges scores from 0 to 100%

    Time frame: 12 months

  3. 1 Minute Walk Test - Gait Speed (m/s)

    Performed at each clinical visit, the participant will complete the 1 Minute Walk Test. Gait speed will be measured using LEGSys.

    Time frame: 12 months

  4. Digital Occulomotor Assessments - Median velocity (pixel/s)

    Using a study tablet, participants will perform a series of oculomotor assessments (saccades). The video will be analyzed to calculate the median velocity of the pupil during saccade movements.

    Time frame: 12 months

  5. EuroQoL 5-Dimension 5-Level questionnaire (EQ-5D-5L)

    The EQ-5D-5L is a standardized 5-item tool used to measure health-related quality of life. EQ-5D-5L scores are interpreted by analyzing three distinct components: a 5-digit health profiles. Each dimension uses five severity levels (1 = no problems, 2 = slight, 3 = moderate, 4 = severe, 5 = extreme/unable to).

    Time frame: 12 months

  6. 1 Minute Walk Test with Cognitive Load- Gait Speed (m/s)

    Performed at each clinical visit, the participant will complete the 1 Minute Walk Test with cognitive load (counting backwards). Gait speed will be measured using LEGSys.

    Time frame: 12 months

  7. Timed Up and Go (TUG) - Sit to Stand duration (s)

    Performed at each clinical visit, the participant will complete the TUG Test. Sit to stand duration will be measured using LEGSys.

    Time frame: 12 months

  8. 30S Chair Sit to Stand - Sit to Stand duration (s)

    Performed at each clinical visit, the participant will complete the 30S Chair Sit to Stand Test. Sit to stand duration will be measured using LEGSys.

    Time frame: 12 months

  9. Digital Occulomotor Assessment - Median duration (s)

    Using a study tablet, participants will perform a series of oculomotor assessments (saccades). The video will be analyzed to calculate the median duration of the pupil during saccade movements.

    Time frame: 12 months

  10. EQ-VAS (Visual Analog Scale)

    The EQ VAS: The participant self-rates their overall health on a vertical thermometer-like scale from 0 to 100, where 100 is the best health the participant can imagine, and 0 is the worst health the participant can imagine.

    Time frame: 12 months

Other outcomes

  1. Digital Fine Motor Control Assessment - Number of taps (count)

    Using a study tablet, participants will perform a series of tapping tests. The tablet will calculate the count of all recorded taps made by a finger on the screen.

    Time frame: 12 months

  2. Digital Fine Motor Control Assessment - Average tap rate (s)

    Using a study tablet, participants will perform a series of tapping tests. The tablet will calculate the number of taps per second.

    Time frame: 12 months

07

Study locations

2 sites
  • Johns Hopkins University School of Medicine
    Lutherville, Maryland 21093, United States
    • Ashley Kucharski · Contactakuchar4@jh.edu
    • Liana Rosenthal, MD PhD · Principal investigator
  • Columbia University Irving Medical Center/Neurological Institute of New York
    New York, New York 10032, United States
08

References and documents

Publications

  • Shah VV, Rodriguez-Labrada R, Horak FB, McNames J, Casey H, Hansson Floyd K, El-Gohary M, Schmahmann JD, Rosenthal LS, Perlman S, Velazquez-Perez L, Gomez CM. Gait Variability in Spinocerebellar Ataxia Assessed Using Wearable Inertial Sensors. Mov Disord. 2021 Dec;36(12):2922-2931. doi: 10.1002/mds.28740. Epub 2021 Aug 23. PubMed 34424581 ↗
  • Zhou H, Nguyen H, Enriquez A, Morsy L, Curtis M, Piser T, Kenney C, Stephen CD, Gupta AS, Schmahmann JD, Vaziri A. Assessment of gait and balance impairment in people with spinocerebellar ataxia using wearable sensors. Neurol Sci. 2022 Apr;43(4):2589-2599. doi: 10.1007/s10072-021-05657-6. Epub 2021 Oct 19. PubMed 34664180 ↗
09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Dec 2026; primary completion for Dec 2028, 24 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 16, 2026
First posted
Oct 1, 2026
StartEst.
Dec 15, 2026
Primary completionEst.
Dec 31, 2028
CompletionEst.
Jan 31, 2029
Last update
Oct 1, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Oct 1, 2026
Show all 1 update
  1. Oct 1, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07851376
Lead sponsor
BioSensics
Responsible party
Sponsor
First posted
Oct 1, 2026
Start date
Dec 15, 2026 (estimated)
Primary completion
Dec 31, 2028 (estimated)
Completion
Jan 31, 2029 (estimated)
Last update
Oct 1, 2026

Study contacts

Ana Enriquez
Contact
ana.enriquez@biosensics.com
8885896213

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion